Ebeling joins Qiagen as part of a process launched by the supervisory board in 2020 to further complement and enhance the board's already extensive experience in Life Sciences and diagnostics.
The addition of Ebeling brings the number of current supervisory board members to eight.
Ebeling has been an advisor in recent years to various businesses after having served as the CEO of the German media group ProSiebenSat Media (OTC: PBSFY) from 2009 to 2018.
Prior to that, he worked for the global healthcare company Novartis (NYSE: NVS) from 1997 to 2008, including roles as CEO of Novartis Pharmaceuticals and also as CEO of Novartis Consumer Health.
He began his career in 1987 and held various positions in marketing and sales in the consumer goods industry before joining Novartis.
Ebeling, who has a degree in psychology from the University of Hamburg, has previously served on the supervisory boards of Bayer AG (OTC: BAYZF) and Lonza AG (OTC: LZAGF).
The National Pharmaceutical Council names new president and chief executive officer
Ascentage Pharma names new independent non-executive director
Applied Pharmaceutical Innovation adds Dr Michael Houghton to Scientific Advisory Board
Russia registers the world's first vaccine against COVID-19 for animals
Exo Therapeutics Names Mahanthappa to Board of Directors, Roberts to Scientific Advisory Board
Astellas Pharma's XOSPATA meets primary overall survival endpoint in phase three confirmatory trial
Vitelliform Maculopathy Patient Treated in Israel with OpRegen Under Named Patient Compassionate Use
Johnson and Johnson Executive Wengel Named to Labcorp Board of Directors
Brazil's Butantan Institute to seek regulatory approval for trials of new COVID-19 vaccine